(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 February 2011 (03.02.2011)

PCT

(10) International Publication Number
WO 2011/012538 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
C07D 487/04 (2006.01) *A61P 9/12* (2006.01)

(21) International Application Number:
PCT/EP2010/060679

(22) International Filing Date:
23 July 2010 (23.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09290599.1 29 July 2009 (29.07.2009) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **STEINHAGEN, Henning** [DE/DE]; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main (DE). **SCHEIPER, Bodo** [DE/DE]; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main (DE). **MATTER, Hans** [DE/DE]; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main (DE). **MCCORT, Gary** [US/FR]; Sanofi-Aventis, Département Brevets, 174, avenue de France, F-75013 Paris (FR). **BÈGIS, Guillaume** [FR/FR]; Sanofi-Aventis, Département Brevets, 174, avenue de France, F-75013 Paris (FR). **GOBERVILLE, Pascale** [FR/FR]; Sanofi-Aventis, Département Brevets, 174, avenue de France, F-75013 Paris (FR). **THIERS, Bérangère** [FR/FR]; Sanofi-Aventis, Département Brevets, 174, avenue de France, F-75013 Paris (FR).

(74) Agent: **KUJATH, Eckard**; Sanofi-Aventis Deutschland GmbH, Patents Germany Industriepark Höchst, Geb. K 801, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/012538 A1

(54) Title: CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS



Ia Ib

(57) Abstract: The present invention relates to cyclic indolizinecarboxamides and azaindolizinecarboxamides of the formulae Ia and Ib, (Ia) (Ib) wherein R, R^a, R^{10}, R^{20}, R^{30}, R^{40}, Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.